^
    Back
    Association details:
    Biomarker:SLC29A1 overexpression
    Cancer:Pancreatic Cancer
    Drug:gemcitabine (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancers (Basel)
    Title:

    hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA

    Published date:
    11/17/2021
    Excerpt:
    High hENT1 protein was prognostic with gemcitabine; median overall survival was 26.0 v 16.8 months (p = 0.006)....hENT1 protein expression...was prognostic for patients treated with gemcitabine, despite 20% fewer patients being included in the current analysis (HR = 0.60 (95% CI = 0.42–0.86), Wald χ2 = 7.90, p = 0.05). The median survival was 26.0 (95% CI = 21.2–32.8) months for high expressers (as defined previously [23]) compared with 16.8 (95% CI = 14.1–24.8) months for low expressers (χ2 = 7.58, p = 0.006) (Figure 2C,D).
    DOI:
    10.3390/cancers13225758
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Mol Cancer Ther
    Title:

    EMT-induced gemcitabine resistance in pancreatic cancer involves the functional loss of equilibrative nucleoside transporter 1

    Published date:
    12/09/2020
    Excerpt:
    In gemcitabine-treated mice, EpCAM positive tumors had high ENT1 expression and reduced metastasis...ENT1 plasma membrane expression positively predicted median overall survival times in patients treated with adjuvant gemcitabine.
    DOI:
    10.1158/1535-7163.MCT-20-0316